Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
  Breaking News: FDA Approves Triumeq, New Once-Daily Combination Pill
  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

Medical News

Peregrine's Tarvacin Safe in First Hepatitis C Trial

February 28, 2006

On Monday, Tustin, Calif.-based Peregrine Pharmaceuticals Inc. said its drug candidate Tarvacin appeared "safe and well-tolerated" in an early-stage clinical trial of hepatitis C patients. The drug is designed to stimulate the body's immune defenses to kill hepatitis C virus particles and infected cells. In the single-dose Phase I trial, the drug was administered to 24 patients with chronic hepatitis C who had either failed on or were no longer responding to standard treatments. Peregrine's statement said the Tarvacin "was well tolerated, with no serious adverse events reported at any of the four dose levels tested, and no potential dose limiting toxicities were observed." Adverse effects were said to be "mild, infrequent, transient and likely not drug-related." Later this year, the company hopes to conduct repeat-dose and combination therapy trials of Tarvacin.

Back to other news for February 28, 2006

Adapted from:
Associated Press
02.27.06


  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

This article was provided by CDC National Prevention Information Network. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update.
 
See Also
More HIV News

Tools
 

Advertisement